Multicenter Clinical Performance Study to evaluate Plasma-based RAS Gene Mutation Testing using OncoBEAM RAS CRC assay (LS52R) of Patients having Progressive or Recurrent Colorectal Cancer

Not Applicable

Recruiting

• Conditions: Colorectal cancer

• Registration Number: JPRN-UMIN000023039
• Lead Sponsor: Sysmex corporation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-07-11
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

1)Patients with pathologically confirmed primary colorectal adenocarcinoma
2)Patients aged 20 or older at the time of the informed consent
3)Patients who signed informed consent form
4)Patients whose blood collection is possible before a treatment start
5)Patients confirmed Stage4 colorectal cancer by imaging findings
6)Patients with no previous chemotherapy, or patients whose PD or clinical PD was confirmed before starting next treatment

Exclusion Criteria

1)Patients judged ineligible to participate in the study
2)Patients registered to the study in the past
3)Patients with a history of multiple cancer or with a comorbid multiple cancer
4)Patients with synchronous or metachronous (a disease-free interval of five years or shorter) double cancer
5)Patients with histories of treatment using drugs targeting EGFR such as an anti-EGFR antibody or Regorafenib

Study & Design

• Study Type: Observational
• Study Design: Not specified